Lower SARS-CoV-2 vaccine responses seen in patients with immune-mediated inflammatory diseases
MDedge reports on a series of new studies in the Annals of the Rheumatic Diseases that found 10% of patients with immune-mediated inflammatory diseases (IMIDs) fail to respond properly to COVID-19 vaccinations regardless of medication and suggest those on methotrexate and rituximab may be especially vulnerable to vaccine failure.
HSS rheumatologist Anne R. Bass, MD, said that it is still crucially vital for patients with IMIDs to get vaccinated and for clinicians to follow recommendations to temporarily withhold certain medications around the time of vaccination.
As a coauthor of the American College of Rheumatology’s COVID-19 vaccination guidelines for patients with rheumatic and musculoskeletal diseases, Dr. Bass confirmed they do not plan to make any significant adjustments to the recommendations.
Read the full article at MDedge.com.
Additional coverage: Medscape.com, WebMD.com.